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Introduction
Breast cancer (BC) is a heterogeneous disease characterized by 
at least five molecular subtypes: luminal A, luminal B, human 
epidermal growth factor receptor 2 (HER2)-enriched, normal-
like and basal-like.1 Basal-like breast cancer (BBC), one of the 
most aggressive and lethal subtypes, comprises 15–20% of all BC 
cases.1,2 BBC itself is very heterogeneous, and according to the 
multi-platform analysis performed by the Cancer Genome Atlas 
Network, BBC expresses the highest frequency of mutations 
along with HER2-positive BC.3,4 Because BBC generally lacks 
expression of estrogen receptor (ER), progesterone receptor (PR) 
and HER2, no targeted therapy is available for effective treat-
ment.1,5 Hence, human mammary cell model systems that faith-
fully represent the alterations that are prevalent in BBC would 
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be beneficial to delineate important molecular mechanisms that 
drive this subtype of BC.
This study focuses on alterations in three onco-proteins that 
occur at high frequency in BBC, namely epidermal growth fac-
tor receptor (EGFR), p53 and the phosphatase and tensin homo-
log deleted on chromosome 10 (PTEN).1,4,6,7 EGFR is a tyrosine 
kinase trans-membrane receptor that can activate both the mito-
gen-activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K) pathways. EGFR can be altered in multiple can-
cers and overexpressed in up to 70% of BBC cases.8,9 PTEN, 
a negative regulator of the PI3K pathway, affects proliferation, 
apoptosis, migration, genomic instability and metabolism.10-15 
Decreased PTEN expression, through loss of heterozygosity, 
chromosomal rearrangement and/or epigenetic silencing, is 
observed in over 50% of all BBC cases and in 80% of familial 
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Also, either knock down of p53 or the expression of dominant 
negative mutant p53 (G245S) in MCF10A cells led to near-
normal acini structures with incompletely cleared lumen due 
to decreased apoptosis.48 MCF10A cells lacking PTEN exhib-
ited increased signaling, enhanced growth on plastic, resistance 
to anoikis, but no increase in growth in soft agar.49 Therefore, 
in the above studies in MCF10A cells, single manipulations of 
EGFR, p53 or PTEN could affect different cellular properties 
important for tumorigenesis but none led to transformation of 
mammary cells as measured by the ability to grow in an anchor-
age independent manner. Here, we show that EGFR overexpres-
sion together with inactivation of p53 and PTEN, alterations 
that are frequently observed in BBC, cooperate in cellular 
transformation.
BBCs.7,16-21 A recent paper suggests that PI3K/AKT 
pathway alteration, which can be controlled by either 
EGFR and/or PTEN, is the highest in BBC among 
all BC subtypes.4 Additionally, the tumor suppressor 
p53, which is a regulator of apoptosis, DNA damage 
response, cell cycle and metabolism, has inactivating 
mutations in over 80% of BBCs.1,4,21-23 Furthermore, 
recent data now suggests that the TP53 pathway 
activity is altered within most, if not all, BBCs.4 
Taken together, EGFR, p53 and PTEN are altered at 
high frequency in a large subset of BBC cases, indi-
cating the potential for these genes to cooperate in 
BBC initiation and/or progression in those tumors.
The MCF10A cell line is a powerful human 
mammary cell culture model system for studying 
the genetic insults that can lead to breast cancer. 
MCF10A cells are human, spontaneously immor-
talized, untransformed, non-tumorigenic, mostly 
diploid and lack CDKN2A.17,24-26 These cells depend 
on growth factors and hormones for growth and sur-
vival, form polarized acini-like spheroids in a sus-
pension of extracellular matrix (matrigel), grow in 
monolayers and do not grow in suspension in soft 
agar unless they are transformed by expression of 
one or more onco-proteins.27,28 For example, the 
disruption of proper acini formation in MCF10A 
cells in matrigel has been shown to occur follow-
ing knock-down of BRCA1 or after the expression 
of mutant alleles of PIK3CA, HER2, PCDH8, only 
serine/threonine kinase AKT/PKB, overexpression 
of wild type human growth hormone (hGH), or 
co-expression of EGFR with c-SRC.29-35 MCF10A 
cells have been shown to grow in an anchorage-inde-
pendent manner in soft agar without extracellular 
matrix following overexpression of mutant H-RAS, 
HER2/NeuT (rat c-neu with single activating point 
mutation) or FGFR1.36-38 Furthermore, MCF10A 
cells cluster closely with the BBC subtype in gene 
expression profiling studies and express markers 
commonly associated with a basal epithelial phe-
notype such as high-molecular weight cytokeratins 
and p63.39-41 They lack estrogen and progesterone 
expression and overexpress the MYC oncogene, which is char-
acteristically upregulated in BBC, making these cells potentially 
suitable for modeling BBC tumor progression.42-44
Studies examining the effects of EGFR, p53 and PTEN 
mutations in combination have not been performed in mam-
mary epithelial cells. However, studies examining each altera-
tion alone have been investigated. MCF10A cells expressing a 
knock-in mutant EGFR (delE746-A750) displayed increased 
levels of total and phosphorylated EGFR, but had no advan-
tage in growth or in their ability to form colonies in soft agar.45 
MCF10A cells knocked out for p53 by Weiss et al. were able to 
grow in the absence of EGF.46 Overexpression of a truncated 
dominant-negative p53 (p53DD) did not affect proliferation rate 
in MCF10A cells in media supplemented with growth factors.47 
Figure 1. Modeling basal-like breast cancer through altering eGFR, p53 and pTeN in 
MCF10a cells. (A) studies analyzing loss of pTeN, overexpression of eGFR or loss of 
p53 function have not shown an oncogenic effect individually in mammary epithelial 
cells. Given the high incidence of these alterations in basal-like breast cancer (BBC), 
we hypothesize that loss of pTeN, overexpression of eGFR and loss of p53 function 
together can cooperate to transform MCF10a cells for a model of BBC. (B) eGFR stable 
overexpression alone and an empty control cassette were expressed in MCF10a 
cells. Total and phospho-tyrosine eGFR antibodies were probed to show eGFR was 
overexpressed and active as a kinase. (C) expression of an N-terminal deletion mutant 
p53DD to abrogate p53 function or empty control cassette in MCF10a cells. Lysates 
were probed with an antibody targeting the remaining C-terminal domain of p53. 
Functional validation of this p53DD was shown by lower p21 level in the p53DD 
sample. (D) To study the effect of loss of pTeN, we utilized MCF10a-pTeN-/- cells de-
leted for exon 2 and we confirmed that pTeN protein was not present compared with 
the parental cells. For (B–D), whole protein lysates were harvested after overnight 
starvation with basal media only. Lysates were probed for vinculin or actin as loading 
controls.
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of PTEN (MCF10A-PTEN-/-).49 We validated that MCF10A-
PTEN-/- cells express no PTEN protein as compared with the 
parental line (Fig. 1D). Thus, single alterations to EGFR, TP53 
or PTEN genes engineered in MCF10A cells can model changes 
that are found in a large proportion of BBC tumors, allowing us 
to analyze for their phenotypic effects in mammary cells.
To verify that the changes to EGFR, p53 or PTEN had the pre-
dicted functional effects, we investigated signaling in our mod-
els. Cells expressing EGFR, p53DD or PTEN loss were starved 
overnight and total protein lysates were analyzed by western blot. 
We found that the transduced EGF receptor was functionally 
active by the increased total tyrosine phosphorylation on EGFR 
in the cells overexpressing EGFR as compared with control cells 
(Fig. 1B). Consistent with an effective dominant-negative dis-
ruption of p53 function, the p53DD infected cells displayed a 
decreased level of p21, a critical cell cycle downstream effector 
of p53 activation (Fig. 1C). AKT activation at serine-473 was 
increased by PTEN mutation (Fig. 1D). Therefore, we observed 
signaling changes that were expected as the result of overexpress-
ing EGFR, p53DD or losing PTEN in our system.
EGF-independent growth is feasible only in PTEN-null 
cells and not in EGFR- or p53DD-expressing MCF10As. We 
characterized the growth properties of MCF10A cells harboring 
overexpression of EGFR, p53DD or loss of PTEN to compare 
each alteration’s effect on proliferation under starved conditions. 
Non-transformed cells are dependent on growth factor signaling 
for their ability to proliferate; thus, in the absence of the appro-
priate mitogenic signals, they do not grow.56 Proliferation was 
determined by assessing the relative cell accumulation at differ-
ent time points, as previously described.57 Cells were maintained 
in media devoid of any growth supplement for a period of 20 d. 
When cells expressing different single alterations were compared 
for their ability to grow, we observed distinct differences in their 
proliferation capacity. Consistent with prior observations,49 loss 
of PTEN allowed cells to proliferate without growth factor stim-
ulation (Fig. 2A). MCF10A cells expressing EGFR or p53DD 
did not proliferate under identical conditions. Therefore, whereas 
losing PTEN expression alone was an instigator for cell growth 
in the absence of growth factors, exogenous expression of either 
EGFR or p53DD was not.
Growth in soft agar is not permissible by altering EGFR, p53 
or PTEN individually. Anchorage-independent growth in soft 
agar is a property of transformed cells that best correlates with 
tumorigenesis.58,59 Therefore, we sought to determine the anchor-
age-independent capacity of any single alteration in MCF10A 
BBC model cells to grow in soft agar. MCF10A cells are non-
transformed cells and by themselves do not to form colonies in 
soft agar, as previously established.60 MCF10A cells that overex-
pressed oncogenic H-RasV12, as our positive control cells, induced 
colonies in soft agar (Fig. 2B), as previously reported.36 However, 
none of the singly-modified MCF10A cells grew as colonies in soft 
agar. This is in agreement with previous studies reporting that 
neither an EGFR activating mutant nor a PTEN-null mutant can 
induce colony formation when expressed in MCF10A cells.33,49 It 
has also been shown that p53DD expression in hTERT-immortal-
ized human mammary epithelial cells do not grow in soft agar.55 
Results
Single modifications of PTEN, EGFR and p53 in MCF10A 
affect signaling. We used MCF10A cells to construct a model 
system to reflect changes seen in BBCs. To do so, we stably 
expressed EGFR, p53 and PTEN alterations in these cells to 
study their combinatorial effects on transformation (Fig. 1A). 
To develop a triple modified model of BBC, we first compared 
the effects of altering EGFR, p53 or PTEN alone. To examine 
the effects of EGFR, we stably overexpressed wildtype EGFR 
via retroviral transduction in MCF10A cells and we showed that 
total EGFR protein level was significantly increased (Fig. 1B). 
To model the effect of p53 mutation, we stably overexpressed 
dominant negative p53 (p53DD) in MCF10A cells via retrovi-
ral transduction. The p53DD is a C-terminal fragment of p53 
that forms functionally impaired multimers with the wildtype 
endogenous p53 to abrogate sequence-specific DNA binding.50 
Multiple groups have shown the effectiveness of p53DD in can-
cer models.54,55 The ectopic expression of p53DD was verified 
using an antibody to the C-terminal region in the truncated 
mutant (Fig. 1C). Next, to model PTEN inactivation, we uti-
lized MCF10A cells that harbored a targeted deletion of exon 2 
Figure 2. In vitro tumorigenic properties of single-modified MCF10a 
cells. (A) MCF10a cells expressing eGFR, p53DD, pTeN loss or empty 
control were plated in 48-well plates in quadruplicate and grown with-
out growth factors for a period of 20 d. Cells were stained with crystal 
violet dye at days 0, 5, 13 and 20 and analyzed for growth rate differ-
ences. The means ± sD for the four experiments are shown and statisti-
cal analysis was calculated by chi-square test. (B) soft agar assay of 
MCF10a cells tested for anchorage-independent growth of each single 
alteration in MCF10a cells. MCF10a cells overexpressing constitutively 
active mutant HRAS (RasV12) was utilized as an internal positive control 
for this assay. The means ± sD for the three experiments are shown and 
statistical analysis was calculated by chi-square test.
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which grew under starvation conditions (Fig. 3A). Interestingly, 
neither EGFR-PTEN-/- nor p53DD-PTEN-/- cells grew signifi-
cantly better than PTEN-/- cells alone, suggesting that exogenous 
expression of EGFR or p53DD did not confer a growth advan-
tage under the same conditions. Overall, the increased prolifera-
tion due to PTEN loss was not affected by co-expression of either 
EGFR or p53DD.
Either EGFR or p53DD cooperates with PTEN mutation 
for anchorage-independent colony growth in soft agar. Given 
that MCF10A cells with alterations in EGFR, p53 or PTEN were 
not able to confer anchorage-independent growth individually, we 
sought to find out if double combinations of those altered genes 
would allow for soft agar colony formation. We observed that the 
Individually, none of these three alterations in MCF10A cells con-
fer anchorage-independent growth property in soft agar.
Loss of PTEN affects proliferation regardless of presence 
of EGFR or p53DD. After analyzing the signaling and growth 
phenotype of cells expressing only one alteration at a time, we 
engineered cells to express two alterations to study their combina-
torial effect for BBC modeling. We stably overexpressed wildtype 
EGFR and/or p53DD in MCF10A or MCF10A-PTEN-/- cells 
to generate the three new experimental cell lines, herein 
named EGFR-p53DD, p53DD-PTEN-/- and EGFR-PTEN-/-. 
Additionally, we stably expressed the control vectors as our con-
trol line, herein named ctrl. PTEN-/- cells expressing EGFR or 
p53DD grew better than EGFR-p53DD or ctrl cells, neither of 
Figure 3. Double- and triple-modified cells grow in absence of growth factors and in soft agar. (A) proliferation of cells was assessed for the double- 
and triple-modified cells. Cells were plated in quadruplicate and grown in 48-well plates in media lacking growth factors for a period of 20 d before 
staining cells with crystal violet dye for analysis. as a double-modified control, empty control vectors for both pBaBe-puro and pCMV-hyg (herein 
named ctrl) were expressed in MCF10a cells. The means ± sD for the four experiments are shown and p values were calculated by chi-square test. 
(B–C) soft agar colony assay for the double- and triple-modified cells show their ability to form colonies in an anchorage-independent fashion. each 
cell line was plated in soft agar in triplicate. Representative photographs of colonies were taken at 4× magnification. The means ± sD for the three 
experiments for each line are shown and p values were calculated by chi-square test. (D) signaling was measured for the double- and triple-modified 
lines. Cell lysates were harvested after overnight starvation and analyzed for eGFR, aKT and eRK signaling. Western blot exposures for each antibody 
were taken from the same blot and irrelevant intervening lanes removed.
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cells (p = 0.04) or the ctrl cell line (p = 0.007) (Fig. 3A). Therefore, 
we observed the greatest cooperation in proliferative ability when 
all three alterations were concomitantly present.
We also compared the ability of the triple-modified cells to 
grow colonies in soft agar relative to the double-modified lines 
(Fig. 3B and C). Our results with soft agar show that when all 
three alterations were expressed together, the transformation 
phenotype became more pronounced (Fig. 3B). There was a sta-
tistically significant increase in the average number of colonies 
in EGFR-p53DD-PTEN-/- cells as compared with the double-
modified cells capable of growing in soft agar, EGFR-PTEN-/- 
and p53DD-PTEN-/- cells (p = 2.3 × 10-9 and p = 3.6 × 10-20, 
respectively; Fig. 3C). Therefore, we showed that concomitant 
alteration of EGFR, p53 and PTEN maximized the number of 
colonies in soft agar, a characteristic of transformed cells. The 
triple modified cells were unable to form tumors in SCID mice 
(n = 10) after at least 3 mo.
Triple-modified cells had a notable difference in signaling as 
compared with the double-modified lines. Whereas AKT acti-
vation in EGFR-PTEN-/- cells showed a similar degree as the 
EGFR-p53DD-PTEN-/- cells, EGFR activation was highest in 
EGFR-p53DD and the triple-modified cells (Fig. 3D). Therefore 
high activation of both the AKT and EGFR signaling was seen 
only in the triple modified cells. We observed no ERK activation 
difference between the double- and the triple-modified cells. We 
conclude that the triple modified line was unique in its activation 
of both AKT and EGFR signaling as compared with any of the 
double-modified lines.
Discussion
The ultimate goal of human cancer models is to manipulate genes 
that are altered in human tumors to demonstrate whether their 
expression can lead to tumorigenesis of normal cells.16,61 Previous 
human mammary epithelial cancer cell models have provided 
important insights into critical pathways involved in cancer for-
mation.30,46,49,53,62-64 EGFR, p53 and PTEN alterations frequently 
occur in a relatively large proportion of the basal-like subtype of 
breast cancer, but their combinatorial expression has not been 
examined for cancer initiation in mammary epithelial cells. 
Therefore, we sought to determine if these three onco-proteins 
are able to faithfully model initiation of BBC when expressed in 
MCF10A cells, a well-established model for studying the effects of 
genes in mammary tumorigenesis.28,30-32,38 Here we showed that 
EGFR, p53 and PTEN alterations cooperate in MCF10A cells to 
drive transformation as measured by the ability of cells to grow 
in an anchorage-independent fashion or on plastic in the absence 
of growth factors (Fig. 4). Enhanced growth was associated with 
activation of biochemical signaling on multiple pathways. Our 
cell line models with mutant PTEN and overexpression of EGFR 
and/or p53DD that transform MCF10A cells can serve as a foun-
dation for identifying additional driver insults (epigenetic and/
or genetic) capable of making the cells more transformed and 
tumorigenic in mice.
We demonstrate that cooperation between alteration of 
EGFR, p53 and PTEN caused transformation of MCF10A cells 
double-modified EGFR-PTEN-/- and p53DD-PTEN-/- cells were 
capable of growing colonies in suspension in soft agar (Fig. 3B 
and C). On the other hand, EGFR-p53DD did not cooperate 
to transform cells as measured by growth in soft agar. We saw 
that the double-modified cells expressing PTEN-/- as one of their 
alterations grew significantly more colonies when compared with 
EGFR-p53DD (p = 9.2 × 10-9 when comparing EGFR-p53DD to 
p53DD-PTEN-/-). The lack of soft agar growth by EGFR-p53DD 
cells is consistent with their significantly lower AKT activation 
at threonine-308 residue compared with EGFR-PTEN-/- and 
p53DD-PTEN-/- cells that formed colonies (Fig. 3D, lane 1 com-
pared with lanes 2 and 3). These experiments demonstrate that 
although EGFR-p53DD did not cooperate to grow in suspension 
in soft agar, PTEN loss with either EGFR or p53DD did signifi-
cantly synergize to grow colonies in an anchorage-independent 
fashion. Interestingly, EGFR-PTEN-/- cells grew on average twice 
as many colonies per plate as compared with p53DD-PTEN-/- 
cells (p = 1.6 × 10-5; Fig. 3C), consistent with the known effects of 
EGFR signaling on additional tumor-promoting signaling path-
ways. This result is consistent with higher phosphorylation and 
activation of AKT at threonine-308 in EGFR-PTEN-/- cells as 
compared with p53DD-PTEN-/- cells (Fig. 3D, compare lanes 2 
and 3). Therefore, the ability of either p53DD or EGFR to poten-
tiate soft agar growth in the context of PTEN mutation suggests 
that either altered p53 or EGFR have the potential to cooperate 
with PTEN loss to stimulate tumor progression.
Increased growth by co-expression of PTEN, EGFR and p53 
in cells. Next, we investigated whether all three alterations together 
could show cooperation beyond what was observed with the dou-
ble changes. Cells stably expressing all three changes, herein called 
EGFR-p53DD-PTEN-/-, were compared with the other modified 
cells for their ability to grow in media devoid of all growth fac-
tors. Strikingly, we observed enhancement in the rate of growth 
of EGFR-p53DD-PTEN-/- cells as compared with the various 
double-modified cell lines. Our triple-modified cells proliferated 
significantly more than any of the PTEN-null double-modified 
Figure 4. a MCF10a model for BBC transformation. We demonstrate 
that introducing three highly prevalent somatic alterations (eGFR, p53 
and pTeN) in BBC biopsies was capable of transforming MCF10a cells 
as shown by growth in the absence of growth factors and anchorage-
independent colony formation in soft agar. Given the high frequency of 
other somatic genetic and epigenetic changes found in BBC, additional 
genetic and/or epigenetic changes likely contribute to further trans-
form the eGFR-p53DD-pTeN-/- cell line model in vitro and in vivo.
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Methods
Cell culture. MCF10A-PTEN-/- (clones 1 and 3) and their 
parental line were a kind gift from Kurtis Bachman (Glaxo 
Smith Kline) and Ben Ho Park (Johns Hopkins University).49 
Cells were cultured at 37°C and 5% CO
2
 in DMEM/F12 50:50 
(Fisher Scientific) media supplemented with 5% horse serum, 
20 ng/ml of EGF, 10 μg/ml insulin, 0.5 mg/ml hydrocortisone, 
100 ng/ml cholera toxin and 1% penicillin/streptomycin solu-
tion. For signaling, cells were starved in DMEM/F12 media 
without growth factors overnight and washed twice with cold 
phosphate buffer saline (PBS) before lysis, as described below. 
All experiments were performed with two different MCF10A-
PTEN-/- clones, which showed similar results.
Retroviral production. Stable cell lines were generated by 
serial viral infection of MCF10A or MCF10A-PTEN-/- cells with 
retroviral supernatants expressing pCMV-p53DD-hygromycin 
or pBABE-EGFR-puromycin. The p53DD vector was a gen-
erously kind gift from Moshe Oren (Weizmann Institute of 
Science).50 The EGFR vector was obtained from Addgene (plas-
mid 11011).51 Empty vectors for pCMV and pBABE were used 
as negative controls. Retroviral production in phoenix cells was 
performed as previously described.52 Cultured viral supernatants 
were collected after 48 h. Cells were infected with filtered viral 
supernatants in the presence of 12 μg/ml polybrene (Sigma). 
Post viral infection, successfully transduced polyclonal popula-
tion of cells was obtained when selected with the appropriate 
drugs (hygromycin at 100 μg/ml for p53DD and puromycin at 
1 μg/ml for EGFR).
Immunoblotting. Cells were lysed in 1.25 M TRIS-HCl, 
pH 6.8, 10% β-mercaptoethanol, 10% sodium dodecyl sulfate 
(SDS), 20% glycerol, 0.5% bromophenol blue solution and 8 M 
urea. Protein lysates were boiled for five min and 25 μg of total 
protein was separated on 10% SDS-PAGE gels and transferred 
to polyvinylidene fluoride membranes. Membranes were blocked 
and incubated with primary antibodies followed by second-
ary antibody incubation. The primary antibodies were PTEN 
(6H2.1, Cascade); EGFR (1005, Santa Cruz); phospho-tyrosine 
(4G10, Fisher); p53 (Ab-1, Calbiochem); phospho-EGFR Y-1173 
(Cell Signaling), AKT, phospho-AKT-S473, phospho-AKT-
T308, ERK-p44/42, phospho-ERK-p44/42 (all Cell Signaling) 
and actin (AC-15, Sigma). Membranes were developed with an 
enhanced chemiluminescence detection kit (SuperSignal West 
Pico, Fisher) according to manufacturer’s instructions.
Proliferation assay. MCF10A cells were plated in 48-well 
plates at a density of 1 × 104 cells per well. At the indicated 
time points, cells were washed with PBS and fixed and stained 
with 0.05% crystal violet (JT Baker) in formalin for 20 min. 
Cells were rinsed three times with PBS to remove excess stain 
and allowed to dry overnight. Stained cells were analyzed by 
extracting the cell-associated dye with 1 ml 10% acetic acid per 
well and shaking plates for 3 h at room temperature. Optical 
density was measured at 565 nm. Samples were performed in 
quadruplicates.
Anchorage-independent soft agar growth and transplant 
assays. For soft agar colony formation assays, 2.5 × 104 MCF10A 
as measured by causing both the ability to grow in the absence 
of growth factors and in suspension in soft agar. As cells become 
transformed, they lose their dependence on growth factors and 
are able to grow devoid of them.65 As a single event, losing PTEN 
was the most important alteration in mammary epithelial cells as 
it was the only alteration to cause them to grow in the absence of 
mitogenic stimuli. When all three alterations were expressed, our 
results indicated an additive effect as cells grew the fastest in this 
triple combination in the absence of growth factors. However, 
no single alteration was able to induce growth in soft agar. The 
ability of cells to grow in suspension was only permitted when 
PTEN inactivation cooperated with either loss of p53 function 
through p53DD expression or EGFR overexpression. Thus loss 
of PTEN synergized with p53 or EGFR alteration in this set-
ting. Further synergy in soft agar was observed when all three 
alterations were expressed together to form 2- to 4-fold more col-
onies as compared with the double-modified cells. The additive 
effect observed when EGFR, p53 and PTEN are all altered in the 
anchorage-independent assay is in accordance with the model for 
cancer progression where a series of stepwise alterations have to 
accrue for cells to become transformed and display the different 
hallmarks of cancer.66,67
The substantial difference in phenotype between EGFR-
PTEN-/- and triple-modified cells would indicate an important 
selective pressure to inactivate p53, which is highly supported by 
data showing that over 80% of BBCs have mutations in p53 or in a 
component of its pathway.4 Further work is needed to identify the 
important target proteins coordinating the advantage gained by 
the triple-modified cells. We know that altering EGFR, p53 and 
PTEN pathways can regulate a myriad of crucial functions such 
as proliferation, apoptosis, protein translation, metabolism, DNA 
damage response and cell cycle control, which is likely why the 
triple-modified cells grow better than the double-modified cells.
While no studies have investigated the combined effect of 
altering PTEN, EGFR and p53 together, prior studies have been 
performed in which two of these genes were altered in combina-
tion. PTEN mutation was shown to cooperate with EGFR acti-
vation in human glioblastoma.68 Inactivation of both PTEN and 
p53 was sufficient to induce invasive prostate cancer in a mouse 
model but inactivation of just one alteration was not sufficient 
for tumorigenesis.69 The cooperation between EGFR and p53 
was shown to expand a subpopulation of esophageal cells to go 
through epithelial-to-mesenchymal transition, a phenotype of 
transformed cells.70 Similar to the above studies in other systems, 
we have also found evidence that PTEN deletion cooperates with 
p53 and/or EGFR alteration in mammary epithelial cells.
Our results demonstrate that beyond their individual con-
tributions, the combined alterations of EGFR, p53 and PTEN 
together cooperate to bestow features of cellular transformation 
on MCF10A cells. Therefore, our findings suggest that coinci-
dent molecular alterations of these three genes, which can be 
found in human breast tumor biopsies, contribute to BBC patho-
genesis. Finally, our triple modified MCF10A cell line system for 
BBC may provide a useful platform for pharmacological studies 
to explore the potential therapeutic benefit of simultaneous tar-
geting of these three genes in BBC.
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cells were seeded per 60 mm plate with a bottom layer of 0.6% 
Bacto agar (BD Biosciences) and a top layer of 0.3% Bacto agar, 
both in complete media. Colonies were photographed after three 
weeks of incubation and analyzed. The total number of colonies 
per cell line was counted per plate. Colonies were counted in at 
least four different views to calculate the average value. Soft agar 
was performed in triplicate for each sample. For evaluation of 
cell growth in mice, 1 × 106 cells were injected into the mam-
mary fat pad of female SCID mice (Harlan Laboratories) at 1:1 
ratio with matrigel and monitored by palpation for a minimum 
of three months. Mice were housed in the mouse facility of the 
Irving Cancer Research Center and were treated in accordance 
with Columbia University Institutional Animal Care and Use 
Committee (IACUC).
Statistical analysis. Proliferation rate and soft agar assays were 
analyzed using the chi-square test, with a p value ≤ 0.05 defined 
as statistically significant.
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